Affimed N V (AFMD) Return on Equity ROE from the second quarter 2024 to second quarter 2023 and annually, average high and low, overall ranking from Jun 30 2024 to 0 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Affimed N v   (NASDAQ: AFMD)

Affimed N V 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Affimed N V in the second quarter 2024?
Affimed N V recorded a cumulative net loss of $-167 million during 12 months ending in the second quarter 2024, resulting in a negative return on equity (ROE) of -297.42%.

Within the Major Pharmaceutical Preparations industry 388 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2023 from 3963 to 4632.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2024)
II. Quarter		 (Dec 31 2023)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter
Y / Y Equity Change -52.5 % -62.2 % -57.92 % -62.2 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -167 -151 -128 -128 -117
Return On Equity (TTM) -297.42 % -232.7 % -140.44 % -112.91 % -83.4 %
AFMD's Total Ranking # 4632 # 3963 # 0 # 0 #
Equity (TTM) in Millions 31 65 65 65 65
Seq. Equity Change -52.5 % 0 % 0 % 0 % -62.2 %
Seq. Net Income Change - - - - -

Back to AFMD Management Effectiveness >> AFMD's 5 Years Annual ROE >> Compare AFMD ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 389
Sector # 817
Overall # 4632

Return On Equity Statistics
High Average Low
-42.31 %
-78.59 %
-183.26 %
(Dec 31 2021)   (Dec 31 2023)





AFMD Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Equity in Millions 65 171 152 81 43
Y / Y Equity Change -62.2 % 12.48 % 88.84 % 86.19 % -3.64 %
Net Income in Millions -119 -96 -64 -46 -36
Y / Y Net Income Change - - - - -
Return On Equity -183.26 % -56.24 % -42.31 % -57.46 % -83.7 %

Back to AFMD Management Effectiveness >> AFMD's 5 Years Annual ROE >> Compare AFMD ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AFMD's' Return on Equity at Yahoo Finance
AFMD's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AFMD's Competitors
Subscribers only: Roe for Affimed N V 's Suppliers
Subscribers only: Return On Equity for AFMD's Customers




Companies with similar Return On Equity at Jun 30 2024, within Healthcare Sector ROE

Date modified: 2026-09-18T15:15:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.